Powles TB, Van der Heijden MS, Loriot Y, Bedke J, et al. Enfortumab vedotin plus pembrolizumab in untreated locally advanced or metastatic urothelial carcinoma: 2.5-year median follow-up of the phase III EV-302/KEYNOTE-A39 trial. Ann Oncol 2025;36:1212-1219.
PMID: 40460988